Fluorodopa positron emission tomography with an inhibitor of catechol- O-methyltransferase: Effect of the plasma 3-O-methyldopa fraction on data analysis

Journal of Cerebral Blood Flow and Metabolism

Volumn 16, Issue 5, 1996, Pages 854-863

  Ishikawa, Tatsuya ^a   Dhawan, Vijay ^a   Chaly, Thomas ^a   Robeson, William ^a   Belakhlef, Abdelfatihe ^a   Mandel, Francine ^a   Dahl, Robert ^a   Margouleff, Claude ^a   Eidelberg, David ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

3 O methyl FDOPA (3OMFD); 6 18F fluoro L dopa (FDOPA); Catechol O methyltransferase (COMT) inhibitor; Dopa decarboxylase (DDC) activity; Entacapone (OR 611); Positron emission tomography (PET)

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; CATECHOL METHYLTRANSFERASE; DOPAMINE; ENTACAPONE; LEVODOPA; METHYLDOPA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DECARBOXYLATION; DOPAMINERGIC SYSTEM; DRUG DISTRIBUTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMAGE ANALYSIS; MALE; NIGRONEOSTRIATAL SYSTEM; OCCIPITAL CORTEX; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 0029785290     PISSN: 0271678X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004647-199609000-00010     Document Type: Article

References (16)

1. Backstrom R, Honkanen E, Pippuri A, et al (1989) Synthesis of some novel potent and selective catechoI-O-methyltrans-ferase inhibitors. J Med Chem 32:841-846
2. Brooks DJ, Salmon EP, Mathias CJ, et al (1990) The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain 113:1539-1552
3. Cedarbaum JM, Gandy SE, McDowell FH (1991) "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesia, or dementia in Parkinson's disease. Neurology 41:622-629
4. Cedarbaum JM, Leger G, Guttman M (1991) Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease. Clin Nenropharmacol 14:330-342
5. 82Rb/PET studies of blood-brain-barrier permeability. Phys Med Biol 33:61-74.
6. Dhawan V, Ishikawa T, Patlak C, Chaly T, Robeson W, Belakhlef A, Margouleff C, Mandel F, Eidelberg D (1996) Combined FDOPA and 3OMFD PET studies in Parkinson's disease. J Nucl Med 37:209-216
7. 18FDOPA uptake: Absence of an aging effect. J Cereb Blood Flow Metab 13:881-888
8. 18F]fluoro-L-DOPA in human blood. J Nucl Med 29:363-369
9. Gjedde A (1981) High- and low-affinity transport of D-glucose from blood to brain. J Neurochem 36:1463-1471
10. Gjedde A, Reith J, Dyve S, et al (1991) Dopa decarboxylase activity of the living human brain. Proc Natl Acad Sci USA 88:2721-1725
11. Guttman M, Leger G, Reches A, et al (1993) Administration of the new COMT inhibitor OR-611 increase striatal uptake of fluorodopa. Move Disord 8:298-304
12. Hariz Ml, Erikson AT (1986) Reproducibility of repeated mount-ing of a noninvasive CT/MRI Stereoadapter. Appl Neurophysiol 49:336-347
13. Hoehn MM, Yahr MD (1967) Parkinsonism: Onset, progression, and mortality. Neurology 17:21-25
14. Huang SC, Yu DC, Barrio JR, et al (1991) Kinetics and modeling of L-6-[18F]FIuoro-DOPA in human positron emission tomographic study. J Cereb Blood Flow Metab 11:898-913
15. Ishikawa T, Dhawan V, Chaly T, Margouleff C, Robeson W, Dahl JR, Mandel F, Spetsieris P, Eidelberg D (1996) Clinical significance of striatal DOPA Decarboxylase activity in Parkinson's Disease. J Nucl Med 37:216-222
16. Kaakkola S, Teravainen H, Ahtila S, et al (1994) Effect of OR-611, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 44:77-80